相关实验视频
Updated: Jun 21, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
动态透性对急性缺血性中风中的凝块纤维素含量具有预测价值
Vania Anagnostakou1,2, Daniel Toth1, Gergely Bertalan1
1Department of Neuroradiology, Clinical Neuroscience Center, University Hospital Zürich, Frauenklinikstrasse 10, 8091 Zürich, Switzerland.
动态透性是一种成像生物标志物,揭示了对急性缺血性中风凝块组成的洞察力. 富含纤维素的血块显示出明显的对比吸收模式,有助于理解中风血栓的特征.
科学领域:
- 神经辐射学神经辐射学
- 干预神经病学 干预神经病学
- 生物标志物开发 生物标志物开发
背景情况:
- 急性缺血性中风 (AIS) 是导致残疾的主要原因.
- 机械血栓切除术 (MT) 是大血管封闭 (LVO) AIS的关键治疗方法.
- 了解凝块组成对于优化MT结果至关重要.
研究的目的:
- 研究在接受MT治疗的AIS患者的动态透析率和凝块组成之间的相关性.
- 评估动态透性作为对血栓特征的成像生物标志物.
主要方法:
- 分析了接受MT的39名LVO AIS患者.
- 在MT前进行了三相CT成像,以评估动态通透性.
- 获取的血块经历了组织病理学分析以确定组成 (富含红细胞,富含纤维素/血小板,混合).
主要成果:
- 富含纤维素的血块和富含红细胞/混合血块之间的动态透性模式有显著差异.
- 富含纤维素的血块在"没有冲洗的吸收"类别相比"带有冲洗的吸收" (p=0.036) 较少.
- 相反的吸收模式,包括洗,显著预测了富含纤维素的血块的可能性.
结论:
- 动态透性是一种有前途的成像生物标志物,用于表征AIS凝块组成.
- 特定的对比吸收和洗模式与富含纤维素的血栓相关,可能指导治疗策略.
- 进一步的研究可以探索动态透性在预测MT成功方面的临床实用性.
更多相关视频
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
07:09Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
相关概念视频
Clot Retraction and Fibrinolysis
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins